WHO plans to evaluate raw materials prompt industry cost worries
This article was originally published in Scrip
Executive Summary
World Health Organization (WHO) plans to evaluate active pharmaceutical ingredients (APIs) is worrying industry. WHO is starting a pilot where it will prequalify selected APIs because the globalisation of drug production has made it difficult to verify their quality. However, the pharmaceutical industry is concerned the pilot may increase company costs while a US think tank is worried it may take away from the WHO's core business.